Get the Stockscreener App
18.18
2.10%
-0.39
After Hours:
18.20
0.02
+0.11%
Dbv Technologies Adr stock is traded at $18.18, with a volume of 93,032.
It is down -2.10% in the last 24 hours and down -7.43% over the past month.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
See More
Previous Close:
$18.57
Open:
$18.8
24h Volume:
93,032
Relative Volume:
0.42
Market Cap:
$1.08B
Revenue:
-
Net Income/Loss:
$-147.32M
P/E Ratio:
-3.4476
EPS:
-5.2733
Net Cash Flow:
$-122.10M
1W Performance:
-7.48%
1M Performance:
-7.43%
6M Performance:
+32.22%
1Y Performance:
+107.30%
1-Day Range:
$18.03
$18.80
1-Week Range:
$18.03
$19.57
52-Week Range:
$7.5262
$26.18
Dbv Technologies Adr Stock (DBVT) Company Profile
Name
Dbv Technologies Adr
Sector
Industry
Phone
33(0)155427878
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
18.18 | 1.10B | 0 | -147.32M | -122.10M | -5.2733 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-25 | Initiated | Guggenheim | Buy |
| May-29-25 | Resumed | Goldman | Sell |
| Jan-04-23 | Upgrade | Societe Generale | Hold → Buy |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| May-10-22 | Downgrade | Goldman | Buy → Neutral |
| Sep-14-21 | Upgrade | Societe Generale | Hold → Buy |
| Jan-22-21 | Downgrade | Societe Generale | Hold → Sell |
| Nov-02-20 | Upgrade | Societe Generale | Sell → Hold |
| Aug-06-20 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy |
| Dec-16-19 | Initiated | Citigroup | Buy |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Jun-17-19 | Initiated | Goldman | Buy |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-20-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-20-18 | Downgrade | Jefferies | Buy → Hold |
| Dec-20-18 | Downgrade | Stifel | Buy → Hold |
| Oct-31-17 | Upgrade | Societe Generale | Sell → Hold |
| Oct-24-17 | Downgrade | Societe Generale | Buy → Sell |
| Oct-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-23-17 | Initiated | Deutsche Bank | Buy |
| Mar-16-17 | Upgrade | Societe Generale | Hold → Buy |
| Sep-26-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-15 | Initiated | Barclays | Overweight |
| Oct-23-15 | Initiated | BofA/Merrill | Buy |
View All
Dbv Technologies Adr Stock (DBVT) Latest News
MPM BioImpact reports 8.8% stake in DBV Technologies (DBVT) - Stock Titan
Combined General Meeting of June 3, 2026 - The Manila Times
Adage insiders report 22,272,884 shares in DBV Technologies (NASDAQ: DBVT) - Stock Titan
Artisan Partners (DBVT) discloses 2,219,386 ADS; 3.7% stake reported - Stock Titan
Vivo Opportunity (DBVT) holds 2.36M ADSs — 4.0% ownership disclosed - Stock Titan
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq - The Manila Times
DBV Technologies (DBVT) grants 1.74M performance share units to CEO - Stock Titan
Invus affiliates disclose 17.998M DBV ordinary shares (DBVT) — 6.1% reported - Stock Titan
DBVT Stock Price, Quote & Chart | DBV TECHNOLOGIES SA-SPON ADR (NASDAQ:DBVT) - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
DBV Technologies (DBVT) ramps Q1 2026 spending but extends cash runway - Stock Titan
DBV Technologies Reports First Quarter 2026 Financial Results - The Manila Times
Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
DBV Technologies (NASDAQ: DBVT) director Philina Lee files initial Form 3 ownership - Stock Titan
Wall Street Analysts Predict a 79.04% Upside in DBV Technologies (DBVT): Here's What You Should Know - Zacks Investment Research
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight - GlobeNewswire Inc.
Goldman Sachs Keeps Their Sell Rating on DBV Technologies SA – American (DBVT) - The Globe and Mail
Combined General Meeting of June 11, 2025 - NTB Kommunikasjon
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
DBV technologies S.A. (ADR) (DBV1.SG) Stock Forum & Discussion - Yahoo! Finance Canada
DBV technologies S.A. (ADR) (DBV1.SG) Stock Major Holders - Yahoo! Finance Canada
DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Friday - Defense World
DBV technologies S.A. (ADR) (DBV1.SG) company profile and facts - Yahoo Finance UK
DBV Technologies: A Tough Nut To Crack In A Shrinking Market (NASDAQ:DBVT) - Seeking Alpha
Guggenheim Reiterates “Buy” Rating for DBV Technologies (NASDAQ:DBVT) - Defense World
Alphabet To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
DBV Technologies Reports Full Year 2025 Financial Results and Business Update - markets.businessinsider.com
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document - The Manila Times
DBV Technologies (NASDAQ: DBVT) deepens 2025 loss but funds runway into 2027 - Stock Titan
Peanut patch developer DBV says cash funds operations into Q2 2027 - Stock Titan
Hesai Group, BitFuFu And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review - The Manila Times
DLD Asset Management LP Makes New $250,000 Investment in DBV Technologies S.A. $DBVT - Defense World
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP), Chemomab Therapeutics (CMMB) and Reviva Pharmaceuticals Holdings (RVPH) - The Globe and Mail
DBV Technologies to Participate in Upcoming March Investor Conferences - The Manila Times
Biotech DBV Technologies lines up back-to-back March investor events - Stock Titan
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 - ChartMill
Guggenheim Sticks to Their Buy Rating for DBV Technologies SA – American (DBVT) - The Globe and Mail
DBV Technologies stock surges on new peanut patch trial data - Investing.com
Phase 3 VITESSE data highlighted by DBV Technologies (NASDAQ: DBVT) - Stock Titan
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting - The Manila Times
DBV Technologies Highlights Additional Data from Successful - GlobeNewswire
DBV Technologies (DBVT) Projected to Post Earnings on Thursday - Defense World
European ADRs Were Flat As Biotech Names Took The Lead - Finimize
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail
Dbv Technologies Adr Stock (DBVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):